PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023.
The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until August 19, 2023 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5465238.
The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Thursday, August 10, 2023. The Company anticipates no change to the preliminary sales results for the second quarter of 2023 that were disclosed on July 11, 2023.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company, after the market closes on Thursday, August 10, 2023.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
Contacts:
Michael F. Brigham, President and CEO
ImmuCell Corporation
(207) 878-2770
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
(602) 889-9700
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.06 |
| Daily Change: | -0.11 -2.13 |
| Daily Volume: | 2,555 |
| Market Cap: | US$45.080M |
November 13, 2024 February 27, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
